Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 18Obesity 2Neoplasm Metastasis 2Vitamin D Deficiency 1Sleep Wake Disorders 1Recurrence 1Precancerous Conditions 1Nutrition Disorders 1Neoplasms 1Muscle Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Hormone-receptor-positive Breast Cancer 1Endometrial Neoplasms 1Depression 1Chronic Pain 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Organoids 1Arthralgia 1

Interventions

Venlafaxine Hydrochloride 1Tamoxifen 1Sertraline 1Genetic Testing 1Gabapentin 1Escitalopram 1Citalopram 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Hot Flashes × Tamoxifen × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡